Pair Name	Morusin, MAPK pathway inhibitors
Disease Info	[ICD-11: 2C30]	Melanoma		Investigative
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Expression	MYC	hsa4609
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	PCNA	hsa5111
	Down-regulation	Expression	SOX2	hsa6657
	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	A-375	Amelanotic melanoma	Homo sapiens (Human)	CVCL_0132
In Vivo Model	A375 and A375R cells (1×10⁵, in 100 μL of phosphate-buffered saline) were subcutaneously injected into the right hind legs of 4-week-old male BALB/c nude mice.
Result	Our results suggested that the combination of morusin and MAPK pathway inhibitors may be a more effective treatment strategy for BRAF-mutant melanoma than MAPK pathway inhibitors alone.